On March 24, 2026, RenovoRx, Inc. announced the appointment of Ramtin Agah, M.D., as the Executive Chairman of the Board, effective February 27, 2026. This new role comes alongside his existing position as Chief Medical Officer. The company has also disclosed the terms of his new compensation package, which includes an annualized base salary of $450,000, contingent upon a minimum of 30 hours of work per week. Dr. Agah will also be eligible for an annual discretionary bonus of up to 40% of his base salary, based on both company and individual performance. The first bonus is expected to be paid in 2027 for the performance of 2026. Furthermore, Dr. Agah will have the opportunity to receive annual grants of stock options and other equity awards under the company’s 2021 Omnibus Equity Incentive Plan, subject to the terms and conditions of the plan. This strategic leadership change is anticipated to enhance the company's operational execution and governance controls, potentially leading to improved performance and shareholder value in the future.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.